)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Eledon Pharmaceuticals
Eledon Pharmaceuticals (ELDN) investor relations material
Eledon Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary19 Mar, 2026
Executive summary
Advanced tegoprubart as a next-generation immunosuppressive therapy, with over 100 patients treated across transplantation programs.
Achieved key milestones, including Orphan Drug designation for tegoprubart in liver transplantation and positive clinical data in kidney and islet cell transplantation.
Financial highlights
Research and development expenses for 2025 were $66.3 million, up from $52.0 million in 2024, driven by expanded clinical trials and manufacturing scale-up.
General and administrative expenses for 2025 were $17.0 million, down from $18.6 million in 2024, mainly due to lower stock-based compensation.
Net loss for 2025 was $45.6 million ($0.52 per share), compared to $36.2 million ($0.66 per share) in 2024; excluding non-cash warrant liability gains, net loss was $79.1 million in 2025 and $67.1 million in 2024.
Cash and cash equivalents plus short-term investments totaled $133.3 million at year-end 2025, down from $140.2 million at year-end 2024.
Outlook and guidance
Anticipates FDA guidance and initiation of Phase 3 trial for tegoprubart in kidney transplantation.
Plans to initiate additional islet and liver transplantation trials and report long-term data from ongoing studies.
Tegoprubart eGFR trend from 12 to 24 months
Tegoprubart vs tacrolimus safety in islet study
Impact of warrant fair value on 2025 net loss
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Eledon Pharmaceuticals
- Tegoprubart advances with strong safety, phase 3 plans, and expanding transplant indications.ELDN
Leerink Global Healthcare Conference 202611 Mar 2026 - Promising transplant therapy advances to phase III, with expansion into islet and xenotransplant studies.ELDNGuggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026
- Key phase 2 transplant data and strong financial runway position the program for major milestones.ELDNGuggenheim Securities Inaugural Healthcare Innovation Conference14 Jan 2026
- Phase II kidney transplant data for tegoprubart expected Q4, aiming for superior efficacy and safety.ELDNGuggenheim SMID Cap Biotech Conference29 Dec 2025
- Tegoprubart advances with strong transplant data, pivotal trials, and broad expansion plans in 2024.ELDNLeerink’s Global Healthcare Conference 202518 Dec 2025
- Up to $250M in securities registered, including $75M ATM equity, to fund immunology pipeline and operations.ELDNRegistration Filing16 Dec 2025
- Tegoprubart matched tacrolimus in efficacy but showed a superior safety profile in kidney transplants.ELDNPiper Sandler 37th Annual Healthcare Conference4 Dec 2025
- Annual meeting to vote on directors, share increase, officer exculpation, and auditor ratification.ELDNProxy Filing2 Dec 2025
- Annual meeting to vote on directors, share increase, officer exculpation, and auditor ratification.ELDNProxy Filing2 Dec 2025
Next Eledon Pharmaceuticals earnings date
Q1 202612 May, 2026
Eledon Pharmaceuticals
Next Eledon Pharmaceuticals earnings date
Q1 202612 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage